Toonaangevende onderzoekers presenteren 24-Plex digitale PCR-assay en nieuwe multiplex toepassingen die op unieke wijze mogelijk worden gemaakt door Stilla’s 6-kleuren naica®-systeem
Het eerste 6-kleuren digitale PCR-systeem in de branche beantwoordt aan de marktbehoeften voor hogere prestaties en multiplex technologie
BOSTON & PARIJS–(BUSINESS WIRE)– Stilla Technologies, het multiplex digitale PCR-bedrijf, heeft samen met onderzoekers van SAGA Diagnostics een 24-plex digitale PCR-test gepresenteerd die is gegenereerd op Stilla’s zeskleuren naica®-systeem. Ter gelegenheid van de wereldwijde commerciële lancering van het platform op de American Society of Human Genetics (ASHG) 2021 Virtual Meeting, benadrukten Stilla’s medeoprichter en Chief Technology Officer Rémi Dangla, PhD, en onderzoekers van SAGA Diagnostics, Fred Hutchinson Cancer Research Center en de Universiteit van Athene de nieuwe gegevens tijdens een discussie over hoe zeer gevoelige, multiplex digitale PCR-technologie complexe genomische gegevens omzet in bruikbare inzichten in een breed scala aan onderzoeks- en klinische toepassingen.
Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20211015005140/en/
Leading Researchers Present 24-Plex Digital PCR Assay and Novel Multiplex Applications Uniquely Enabled by Stilla’s 6-Color naica® system
Industry’s First 6-Color Digital PCR System Answers Market Needs for Higher Performance and Multiplexing Technology
BOSTON & PARIS–(BUSINESS WIRE)– Stilla Technologies, the multiplex digital PCR company, joined researchers from SAGA Diagnostics in presenting a 24-plex digital PCR assay generated on Stilla’s six-color naica® system. To mark the platform’s global commercial launch at the American Society of Human Genetics (ASHG) 2021 Virtual Meeting, Stilla’s Cofounder and Chief Technology Officer Rémi Dangla, PhD, and researchers from SAGA Diagnostics, Fred Hutchinson Cancer Research Center, and University of Athens highlighted the new data during a discussion on how highly sensitive, multiplex digital PCR technology is transforming complex genomic data into actionable insights across a breadth of research and clinical applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211015005140/en/
Stilla’s six-color naica® system, the industry’s first six-color digital PCR system, answers market needs for higher performance and multiplexing technology. Learn more here: www.stillatechnologies.com/6-color-dpcr (Photo: Business Wire)
The six-color naica® system is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Scientists are already using Stilla’s technology to advance their research and discovery across wide applications including cell and gene therapies, cancer and liquid biopsy studies, infectious disease detection including SARS-CoV-2 variant detection in wastewater, and food and environmental testing. Additional information on six-color digital PCR can be found here: www.stillatechnologies.com/6-color-dpcr.
“Modern genetics increasingly relies on more complex signatures from scarce samples to inform on a variety of biological events such as early and residual disease detection, drug mechanism of action and efficiency in patients or full characterization of products for use in gene and cell therapy. Building upon the well-established three-color naica system’s ease-of use and transparency of data delivered, our six-color naica system is democratizing digital PCR and enabling the world’s most powerful platform of its kind,” said Dr. Dangla. “From quantifying circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in liquid biopsies for oncology, to detecting low-level genetic variants in infectious diseases, multiplex digital PCR is allowing researchers to parse complex genomics data to gain real-world, clinical insights at both the patient and the population level.”
Registered ASHG 2021 attendees are encouraged to tune in here to join Dr. Dangla and other scientists from Stilla Technologies at the following upcoming sessions:
Presenter: Rémi Dangla, PhD, Cofounder and Chief Technology Officer
Topic: Democratizing digital PCR to bridge the gap between genomics data and genetics insights
Time: October 20, 2021, at 9 AM EDT
Presenter: Kimberley Gutierrez, PhD, Field Applications and Scientific Support Manager
Topic: User-friendly high-plex digital PCR for absolute quantitation of genetic targets
Time: October 21, 2021, at noon EDT
About Stilla Technologies
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla’s groundbreaking Crystal Digital PCR™ solution, the naica® system, is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China. To learn more, visit www.stillatechnologies.com and connect with Stilla on Twitter, LinkedIn and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211015005140/en/
Contacts
Media
Rachel Huff